Últimas noticias sobre Illumina (NASDAQ:ILMN) Bolsa

ILLUMINA INC

Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Ark Invest's Cathie Wood Says Belief In Bitcoin's $1.5 Million Price Target By 2030 Has Grown

Equities

News

Markets

ETFs

ARKG

ARKK

GTLB

ILMN

IRDM

PATH

Ark Invest realizó movimientos estratégicos en el sector tecnológico, ajustando su portafolio con compras clave y ventas millonarias.

Cathie Wood apuesta por Tempus AI y AMD mientras reduce su posición en Meta

SPDR Dow Jones Industrial Average ETF Trust

GILD

NVDA

PYPL

STLA

TSLA

Las acciones del S&amp;P 500 y Nasdaq caen mientras Nvidia y Tesla sufren pérdidas. Descubre qué está impulsando la volatilidad del mercado.

Acciones en rojo: Nvidia, Tesla y PayPal sufren fuertes caídas en medio de incertidumbre

PLTR

ROKU

TWST

Ark Invest vendió más de 135.000 acciones de Palantir Technologies Inc. tras su récord en bolsa. ¿Estrategia o señal de alerta?

Cathie Wood reduce posición en Palantir (PLTR) tras resultados récord: ¿Oportunidad o advertencia?

Illumina Inc

Illumina Inc COM-WHEN ISSUED

RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and lowers the price target from $128 to $112.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Illumina, Lowers Price Target to $112

In the preceding three months, 14 analysts have released ratings for Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $135.86, along with a high estimate of $247.00 and a low estimate of $85.00. Experiencing a 14.17% decline, the current average is now lower than the previous average price target of $158.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1744048815_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Illumina among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $85.00&#x7C;$90.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $128.00&#x7C;$247.00 &#x7C; 
&#x7C;Mason Carrico &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $156.00&#x7C;$156.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $115.00&#x7C;$135.00 &#x7C; 
&#x7C;Catherine Ramsey &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$127.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$130.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $136.00&#x7C;$150.00 &#x7C; 
&#x7C;David Westenberg &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $190.00&#x7C;$185.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $100.00&#x7C;$130.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $247.00&#x7C;$250.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $135.00&#x7C;$145.00 &#x7C; 
&#x7C;Subbu Nambi &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $150.00&#x7C;$170.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $130.00&#x7C;$145.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $150.00&#x7C;$156.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Illumina. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Illumina's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Illumina's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Get to Know Illumina Better</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>A Deep Dive into Illumina's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Illumina's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -1.6% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Illumina's net margin is impressive, surpassing industry averages. With a net margin of 16.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Illumina's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.31%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Illumina's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.04% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Illumina's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Illumina Stock: Analyst Perspectives (14 Ratings)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup cut Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) price target from $90 to $85. Citigroup analyst Patrick Donnelly maintained a Neutral rating. Illumina shares closed at $74.16 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings">view this stock</a>.</li>
<li>Guggenheim slashed the price target for First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) from $304 to $253. Guggenheim analyst Joseph Osha maintained a Buy rating. First Solar shares closed at $128.69 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/FSLR/analyst-ratings">view this stock.</a></li>
<li>Barclays raised Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) price target from $27 to $29. Barclays analyst Andrew Lazar maintained an Overweight rating. Conagra shares closed at $26.68 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/CAG/analyst-ratings">view this stock</a>.</li>
<li>Susquehanna cut the price target for Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) from $34 to $25. Susquehanna analyst Christopher Stathoulopoulos maintained a Neutral rating. Southwest Airlines shares closed at $25.87 on Friday. <a href="https://www.benzinga.com/quote/LLUV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut the price target for Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from $325 to $250. Wedbush analyst Daniel Ives maintained an Outperform rating. Apple shares closed at $188.38 on Friday. See how other analysts view<a href="https://www.benzinga.com/quote/AAPL/analyst-ratings"> this stock</a>.</li>
<li>Jefferies cut Sonos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONO#NASDAQ">SONO</a>) price target from $19 to $13. Jefferies analyst Brent Thill maintained a Buy rating. Sonos shares settled at $8.60 on Friday. <a href="https://www.benzinga.com/quote/SONO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) price target from $500 to $475. Jefferies analyst Brent Thill maintained a Buy rating. Microsoft shares closed at $359.84 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler slashed Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) price target from $105 to $99. Piper Sandler analyst Charles Neivert maintained a Neutral rating. Eastman Chemical shares closed at $75.53 on Friday.  <a href="https://www.benzinga.com/quote/EMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein slashed the price target for General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from $50 to $35. Bernstein analyst Daniel Roeska downgraded the stock from Market Perform to Underperform. GM shares settled at $44.18 on Friday. <a href="https://www.benzinga.com/quote/gm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $76 to $103. Citigroup analyst Paul Lejuez upgraded the stock from Neutral to Buy. Dollar Tree shares closed at $67.55 on Friday. <a href="https://www.benzinga.com/quote/dltr/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07132542/image-69-1024x585.png" alt="" class="wp-image-860474" style="width:569px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07132542/image-69-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07132542/image-69-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07132542/image-69-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07132542/image-69.png 1097w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44665280/how-to-earn-500-a-month-from-walgreens-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Walgreens Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Downgrades

AAPL

DLTR

FSLR

MSFT

SONO

Apple To $250? Here Are 10 Top Analyst Forecasts For Monday

Citigroup analyst Patrick Donnelly maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Neutral and lowers the price target from $90 to $85.

Citigroup Maintains Neutral on Illumina, Lowers Price Target to $85

Illumina's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NYSE">ILMN</a>) short percent of float has fallen 10.32% since its last report. The company recently reported that it has 5.84 million shares sold short, which is 4.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Illumina Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744038030_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Illumina has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Illumina's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Illumina's peer group average for short interest as a percentage of float is 6.42%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About Illumina?

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 7.73% on an annualized basis producing an average annual return of 15.84%. Currently, Illumina has a market capitalization of $12.42 billion. 
Buying $1000 In ILMN: If an investor had bought $1000 of ILMN stock 20 years ago, it would be worth $18,225.19 today based on a price of $78.39 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743551121_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today

Management

Illumina Elects Dr. Scott Gottlieb As Non-Executive Chair

On Friday, March 21, 2025, the Cathie Wood-led Ark Invest made some notable trades, including significant buys and sells.
Ark Invest's fund bought Iridium Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), Pacific Biosciences of California Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) and Absci Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>), while selling Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>).
The IRDM Trade: Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) funds purchased a total of 68,355 shares of Iridium Communications Inc.
The total value of the shares bought, based on the last close price of $27.65, is approximately $1.89 million.
The BEAM Trade: Ark Invest&#8217;s ARKK and Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) funds bought a total of 28,717 shares of Beam Therapeutics Inc.
The total value of the shares bought, based on the last close price of $23.3, is approximately $669,106.
The PACB Trade: Ark Invest&#8217;s ARKK fund bought a whopping 243,300 shares of Pacific Biosciences of California Inc.
The total value of the shares bought, based on the last close price of $1.3, is approximately $316,290.
Other Key Trades:
<ul>
<li>Illumina Inc: Ark Invest sold a total of 42,616 shares through ARKK and ARKG.</li>
<li>Absci Corp: Ark Invest&#8217;s bought 71,392 shares through ARKG.</li>
<li>Repare Therapeutics: Ark Invest sold 54,786 shares through ARKG.</li>
<li>Amgen Inc: Ark Invest sold 990 shares through ARKG.</li>
<li>Veeva Systems Inc: Ark Invest sold 1,322 shares through ARKG.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44434973/tesla-record-highest-trade-ins-amid-backlash-against-ceo-elon-musk-surge-in-vandalism">Tesla Record Highest Trade-Ins Amid Backlash Against CEO Elon Musk, Surge In Vandalism</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

ABSI

AMGN

ARKQ

ARKX

BEAM

PACB

RPTX

VEEV

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round,</a>&#8220; Jim Cramer recommended selling NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>).
On March 7, NANO Nuclear Energy announced that Florent Heidet, Ph.D. has joined NANO Nuclear as its Chief Technology Officer and Head of <a href="https://www.benzinga.com/quote/NNE/news">Reactor Development</a>.
Cramer said Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) is a &#8220;challenged&#8221; company, and he doesn't really care for it.
RBC Capital analyst Conor McNamara, on March 12, maintained Illumina with an Outperform and lowered the price target from $247 to $128.
When asked about Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), he said, &#8220;Keep looking but do not press the button.&#8221;
As per the recent news, Archer Aviation and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), on March 13, collaborated to build the AI foundation for the future of advanced aviation technologies.
The Mad Money host said he has always liked STERIS plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) and recommended buying the stock. &#8220;I think it's just a strong company,&#8221; he added.
Supporting his view, Stephens &amp; Co. analyst Jacob Johnson, on Feb. 6, reiterated Steris with an Overweight rating and maintained a $240 price target.
Cramer said he doesn't know what Sixth Street Specialty Lending, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) really owns, so therefore he can't give his opinion on it.
RBC Capital analyst Kenneth Lee, on Feb. 26, maintained Sixth Street Specialty with an Outperform rating and raised the price target from $23 to $25.
Cramer said he likes Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) very much and recommended to own the stock.
Adding support to his choice, Susquehanna analyst Mehdi Hosseini, on Feb. 20, upgraded Lam Research from Neutral to Positive and raised the price target from $75 to $125.
Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) has been an &#8220;amazing stock for many years,&#8221; Cramer said. He recommended buying the stock.
Supporting his view, UBS analyst David Vogt, on March 5, upgraded Arista Networks from Neutral to Buy and raised the price target from $112 to $115.
Price Action:
<ul>
<li>Illumina shares fell 0.2% to settle at $84.05 on Thursday.</li>
<li>Archer Aviation shares dipped 3.1% to close at $7.25 during the session.</li>
<li>NANO Nuclear Energy shares gained 1.9% to settle at $28.32.</li>
<li>Steris shares fell 0.9% to close at $222.45.</li>
<li>Sixth Street Specialty Lending shares fell 0.9% to close at $21.96 on Thursday.</li>
<li>Lam Research shares fell 1.7% to settle at $75.26.</li>
<li>Arista Networks shares fell 0.1% to close at $80.14 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44298504/top-3-health-care-stocks-youll-regret-missing-this-quarter">Top 3 Health Care Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>
Image: Shutterstock

Media

ACHR

ANET

LRCX

TSLX

Jim Cramer Says Illumina Is 'Challenged,' Recommends Selling This Industrial Stock

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) will likely be one of the top stocks to watch next week. The company's annual GTC conference, often referred to as the Global AI Conference, will take place, and CEO Jensen Huang will once again provide<a href="https://www.benzinga.com/news/24/03/37803088/nvidia-gtc-2024-ceo-huang-highlights-the-past-present-and-future-of-ai-a-new-industry-has-emerged"> a keynote speech.</a>
What Happened: The GTC Conference runs March 17 through March 21, with Huang's keynote coming on March 18 at 1 p.m. ET. The event could serve as <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/44015322/nvidia-analyst-sees-significant-upside-for-stock-with-favorable-riskreward">the next catalyst</a> for the stock, which has fallen in recent months.
Nvidia's AI conference will give the company a chance to highlight new and upcoming products, give updates on demand for items like the Blackwell chips and showcase future monetization opportunities like robotics and automotives.
Nvidia said Huang's <a href="https://www.youtube.com/watch?v=_waPvOwL9Z8">keynote </a>and the event will provide a "glimpse into the future of AI infrastructure, scientific computing, AI and robotics."
"AI is pushing the limits of what's possible — turning yesterday's dreams into today's reality," Huang <a href="https://nvidianews.nvidia.com/news/nvidia-ceo-jensen-huang-and-industry-visionaries-to-unveil-whats-next-in-ai-at-gtc-2025">said</a>. "GTC brings together the brightest scientists, engineers, developers and creators to imagine and build a better future. Come and be first to see the new advances in NVIDIA computing and breakthroughs in AI, robotics, science and the arts that will transform industries and society."
A preview of GTC from <a href="https://techcrunch.com/2025/03/12/nvidia-gtc-2025-what-to-expect-from-this-years-show/">TechCrunch </a>said the expectation is Nvidia shows off an upgraded lineup of the Blackwell chip, like the Blackwell B300 series, codenamed Blackwell Ultra. The chip is slated for a release in the second half of 2025.
The preview also said Nvidia could showcase Rubin, the company's next-gen GPU series, which will be released in 2026.
Huang said on a recent Nvidia earnings call that he would talk about post-Rubin products at GTC, which could mean additional product showcases as the company looks toward 2026 and beyond.
Nvidia will also likely showcase its role in quantum computing. The company will host its <a href="https://www.benzinga.com/news/25/01/43001201/nvidia-announces-first-ever-quantum-day-at-gtc-2025-days-after-jensen-huang-said-quantum-computing-is-20-years-away" target="_blank" rel="noopener">first-ever</a><a href="https://www.benzinga.com/news/25/01/43001201/nvidia-announces-first-ever-quantum-day-at-gtc-2025-days-after-jensen-huang-said-quantum-computing-is-20-years-away"> quantum day </a>at GTC, which will feature executives from several leading companies in the sector.
Read Also: <a href="https://www.benzinga.com/tech/25/03/44309316/dow-curse-strikes-again-nvidias-stock-performance-since-joining-the-index">Dow Curse Strikes Again: Nvidia&#8217;s Stock Performance Since Joining The Index</a>
Why It's Important: Keynotes from Huang and product unveilings have proven to be major catalysts for Nvidia and its stock.
Huang gave a keynote at this year's CES earlier in January. Huang's speech happened after market hours on Jan. 6. Nvidia stock opened at $152.03 on Jan. 7 and hit the all-time high of $153.13 during that day.
Investor optimism in the stock may have peaked around the keynote and product announcements at the event as shares have fallen since then.
With Nvidia stock currently down year-to-date, Huang's GTC keynote could serve as a pivotal moment to create optimism in the company's chips and AI business once again along with some potential new products and catalysts that haven't been factored into the stock.
Other Companies to Watch: Over 25,000 people are expected to attend GTC 2025, which will have over 1,000 sessions and more than 2,000 speakers.
Last year's GTC event provided a boost to several public companies who were mentioned as Nvidia partners by the company.
A current speaker lineup also shows that several public companies will have speakers at the conference, which could make their stocks worth watching for investors as AI continues to be a catalyst watched by analysts and investors.
Here are some of the public companies that have <a href="https://www.nvidia.com/gtc/speakers/">speakers </a>at GTC 2025:
<ul>
<li>Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)</li>
<li>Yum! Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>)</li>
<li>Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>)</li>
<li>PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>)</li>
<li>Salesforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>)</li>
<li>Coca-Cola Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>)</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)</li>
<li>Illumina Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)</li>
<li>Equinix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>)</li>
<li>ServiceNow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)</li>
<li>AT&amp;T Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</li>
<li>The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)</li>
</ul>
While many companies are represented by AI sector executives or chief technology officers, Rivian stands out with its CEO and founder, RJ Scaringe, speaking at the event.
Nvidia's Quantum Day on March 20 could also serve as a catalyst for the overall quantum computing sector and provide a boost for companies speaking, which <a href="https://www.nvidia.com/gtc/sessions/quantum-day/#:~:text=NVIDIA%20founder%20and%20CEO%20Jensen,holds%20for%20useful%20quantum%20computing.">include</a>:
<ul>
<li>D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)</li>
<li>IonQ Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)</li>
<li>Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
</ul>
While there is no guarantee that any company or stock will be as impacted as Nvidia by GTC 2025, investors should know the companies present at the event and be prepared for potential catalysts and press releases related to the event.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41888032/nvidia-ceo-jensen-huang-said-nvidia-has-no-long-term-strategy-how-this-philosophy-is-similar-to-his-reason-to-not-wear-a-watch">Nvidia CEO Jensen Huang Doesn&#8217;t Wear A Watch After A Gardner Taught Him The Secret Of Time</a></li>
</ul>
Photo: jamesonwu1972/Shutterstock.com

AMZN

EQIX

IONQ

QBTS

RGTI

RIVN

Nvidia Stock Reached All-Time Highs After Jensen Huang's CES Keynote — Will Next Week's GTC Spark Another Surge?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B. Riley Securities cut Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) price target from $97 to $89. B. Riley Securities analyst Dave Kang maintained a Buy rating. Ciena shares closed at $63.95 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">view this stock</a>.</li>
<li>Truist Securities boosted the price target for Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) from $163 to $175. Truist Securities analyst Greg Miller maintained a Hold rating. Expedia shares closed at $163.75 on Tuesday. <a href="https://www.benzinga.com/quote/EXPE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $135 to $120. JP Morgan analyst Ryan Brinkman maintained an Underweight rating. Tesla shares closed at $230.58 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">view this stock</a>.</li>
<li>Raymond James slashed the price target for Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) from $245 to $214. Raymond James analyst John Freeman maintained a Strong Buy rating. Diamondback Energy shares closed at $144.65 on Tuesday. <a href="https://www.benzinga.com/quote/FANG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson cut the price target for RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) from $5 to $4. DA Davidson analyst Michael Baker maintained a Neutral rating. RumbleOn shares closed at $3.59 on Tuesday. See how other analysts view<a href="https://www.benzinga.com/quote/RMBL/analyst-ratings"> this stock</a>.</li>
<li>Susquehanna cut Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) price target from $165 to $155. Susquehanna analyst Mehdi Hosseini maintained a Positive rating. Teradyne shares settled at $87.07 on Tuesday. <a href="https://www.benzinga.com/quote/TER/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital slashed Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) price target from $247 to $128. RBC Capital analyst Conor McNamara maintained an Outperform rating. Illumina shares closed at $84.52 on Tuesday. <a href="https://www.benzinga.com/quote/ILMN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Macquarie cut Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) price target from $195 to $185. Macquarie analyst Paul Golding maintained a Neutral rating. Vail Resorts shares closed at $165.42 on Tuesday.  <a href="https://www.benzinga.com/quote/MTN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush cut the price target for Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) from $57 to $12. Wedbush analyst Robert Driscoll downgraded the stock from Outperform to Neutral. Arvinas shares settled at $8.30 on Tuesday. <a href="https://www.benzinga.com/quote/ARVN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised Core Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) price target from $15 to $16. Citigroup analyst Scott Gruber upgraded the stock from Sell to Neutral. Core Laboratories shares closed at $14.62 on Tuesday. <a href="https://www.benzinga.com/quote/clb/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44274110/top-2-industrials-stocks-that-may-collapse-in-march">Top 2 Industrials Stocks That May Collapse In March</a></li>
</ul>

ARVN

CIEN

EXPE

FANG

RMBL

Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday

RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and lowers the price target from $247 to $128.

RBC Capital Maintains Outperform on Illumina, Lowers Price Target to $128

Last week,&nbsp;U.S. President&nbsp;Donald Trump vowed to impose a 25% tariff on imported goods from Mexico and Canada and to double tariffs on&nbsp;<a target="_blank" href="https://www.benzinga.com/news/global/25/02/44010093/trumps-plan-for-canada-mexico-china-tariffs-to-start-march-4-could-shake-stock-market" rel="noreferrer noopener">those from China to 20%</a>.
China responded to Trump&#8217;s recent tariff hikes by placing its own tariffs on certain U.S. goods, sanctioning American companies, and planning to file a complaint with&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/25/03/44117288/after-china-mexico-to-hit-back-against-trumps-tariffs-raising-trade-war-risks" rel="noreferrer noopener">the World Trade Organization</a>.
China also banned imports of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">genetic sequencers</a> from&nbsp;Illumina Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43706143/why-is-ge-healthcare-stock-trading-higher-on-thursday" rel="noreferrer noopener">Why Is GE HealthCare Stock Trading Soaring On Thursday?</a>
Goldman Sachs has grown more confident that end markets are stabilizing and set for a recovery in 2025, despite ongoing policy and tariff uncertainties. Rising demand and increased stimulus are helping ease market bottlenecks.
Following a visit to China, Goldman Sachs analysts see capital equipment markets at a turning point and write that innovation remains a key advantage.
They are also optimistic about GE Healthcare Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) and Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) in the region.
While Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) offers unique technology, economic constraints, and national quotas may limit its growth. Meanwhile, local competition is expanding quickly, but Goldman Sachs sees limited impact due to a lack of technological differentiation. As a result, analyst David Roman upgraded GE Healthcare stock from Neutral to Buy, raising the <a target="_blank" href="https://editorial.benzinga.com/wp-admin/post.php?post=819159&amp;action=edit" rel="noreferrer noopener">price target from $85 to $100</a>.
The analyst has a balanced view on GE Healthcare with stable 4-5% growth in the base business (ex-China), offset by sustained headwinds in the China business (~14% of sales), which would yield top-line growth below consensus and the company&#8217;s medium targets of 4-6% organic revenue growth.
The forecast increase is due to stabilizing trends in China. The analyst expects China sales to return to 2023 levels by 2026, unlike the previous forecast, which did not anticipate a rebound through 2028.
Price Action: GEHC stock is up 0.45% at $85.74&nbsp;at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44251506/inuvo-is-better-aligned-with-consumer-demand-for-privacy-new-regulations-analyst" target="_blank" rel="noreferrer noopener">Inuvo Is Better Aligned With Consumer Demand For Privacy, New Regulations: Analyst</a></li>
</ul>
Photo by PixelBiss via Shutterstock

Analyst Color

Large Cap

Upgrades

Health Care

General

GEHC

ISRG

Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes

On Monday, Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) said that it is implementing cost cuts of approximately $100 million in fiscal year 2025 in response to China's recent ban on importing <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">its sequencers</a>.
Last week, China banned imports of genetic sequencers from&nbsp;Illumina just after U.S. President&nbsp;Donald Trump's&nbsp;additional 10% tariff on Chinese goods took effect.
China accounted&nbsp;for&nbsp;about 7% of Illumina's&nbsp;sales of <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44110625/us-firm-illumina-faces-setback-as-china-blocks-imports-amid-escalating-trade-war" rel="noreferrer noopener">$4.3 billion&nbsp;in 2024</a>.
The diagnostic firm has lowered its 2025 adjusted EPS guidance to $4.50, at the low end of the range of $4.50 to $4.65, compared to the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43544682/illumina-reports-financial-results-for-fourth-quarter-and-fiscal-year-2024" rel="noreferrer noopener">consensus of $4.45</a>.
In February, the Chinese Ministry of Commerce added Illumina and Calvin Klein owner&nbsp;PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) to its list of unreliable entities amid the ongoing&nbsp;<a target="_blank" href="https://www.benzinga.com/news/events/25/02/43455326/illumina-stock-tumbles-nearly-5-overnight-on-robinhood-as-china-adds-ilmn-calvin-klein-owner-pvh-to-u" rel="noreferrer noopener">trade war with the U.S</a>.
China claimed the two companies had disrupted normal market transactions and tried to harm the legitimate rights and interests of Chinese enterprises.
According to Illumina, "These savings would mitigate the impact of a range of potential scenarios for a reduction in revenue and related operating income from the company's Greater China business. The cost reduction program includes optimizing stock-based compensation and non-labor spending and accelerating certain productivity measures."
"Our new fiscal 2025 guidance provides for limited further earnings contribution from China and assumes a continuation of the macro trends we see today," Illumina CFO Ankur Dhingra <a target="_blank" href="https://www.benzinga.com/secfilings/25/03/44236048/illumina-inc-general-corporate-statement-form8" rel="noreferrer noopener">said</a> in a statement.
"We will continue to invest in our growth strategy, while taking actions to achieve EPS of approximately $4.50 in 2025, and then grow from there." "We remain focused on achieving high-single-digit revenue growth by 2027, while expanding our margins," Illumina CEO Jacob Thaysen said in a statement.
Illumina CFO Dhingra <a target="_blank" href="https://www.wsj.com/world/china/illumina-to-cut-100-million-in-costs-lowers-guidance-because-of-china-sales-ban-ff8b495a?mod=latest_headlines" rel="noreferrer noopener">told</a> the Wall Street Journal that the company still runs a facility in China that assembles its older machines. Illumina will also continue selling chemicals and other services to Chinese customers. According to Dhingra, about 90% of the company's global revenue comes from these chemical and service sales.
Price Action: ILMN stock is down 1.24% at $84.90 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44251890/fuelcell-energy-reports-q1-miss-highlights-lower-losses-and-positive-momentum-from-global-restructuring-plan" target="_blank" rel="noreferrer noopener">FuelCell Energy Reports Q1 Miss, Highlights Lower Losses And Positive Momentum From Global Restructuring Plan</a></li>
</ul>
Photo via Shutterstock

Guidance

Diagnostic Kit Maker Illumina To Cut $100 Million In Costs, Lowers 2025 Profit Outlook Amid China Trade Restrictions

Investors with significant funds have taken a bullish position in Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in ILMN usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 62% being bullish and 25% bearish. Of all the options we discovered, 7 are puts, valued at $381,330, and there was a single call, worth $116,000.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $135.0 for Illumina over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Illumina's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Illumina's whale activity within a strike price range from $85.0 to $135.0 in the last 30 days. 
<h3>Illumina Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741713333_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILMN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/25/25</td>
<td>$25.0</td>
<td>$21.8</td>
<td>$23.4</td>
<td>$110.00</td>
<td>$163.8K</td>
<td align="right">0</td>
<td align="right">70</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.1</td>
<td>$9.8</td>
<td>$11.6</td>
<td>$100.00</td>
<td>$116.0K</td>
<td align="right">136</td>
<td align="right">108</td>
</tr>
<tr>
<td>ILMN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$49.5</td>
<td>$47.1</td>
<td>$49.5</td>
<td>$135.00</td>
<td>$59.4K</td>
<td align="right">12</td>
<td align="right">12</td>
</tr>
<tr>
<td>ILMN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.5</td>
<td>$2.35</td>
<td>$2.5</td>
<td>$85.00</td>
<td>$39.5K</td>
<td align="right">694</td>
<td align="right">190</td>
</tr>
<tr>
<td>ILMN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.3</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$95.00</td>
<td>$34.3K</td>
<td align="right">519</td>
<td align="right">151</td>
</tr>
</tbody>
</table>

<h3>About Illumina</h3>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Illumina Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,177,576, the price of ILMN is up by 2.93%, reaching $88.48.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 51 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Illumina</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $130.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays downgraded its action to Underweight with a price target of $100. 
&#x2A; An analyst from Canaccord Genuity persists with their Hold rating on Illumina, maintaining a target price of $115. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Illumina, maintaining a target price of $190. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Illumina, targeting a price of $90. 
&#x2A; In a cautious move, an analyst from Stephens &amp; Co. downgraded its rating to Overweight, setting a price target of $156. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Illumina, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Illumina Unusual Options Activity

Stephens &amp; Co. analyst Mason Carrico reiterates Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Overweight and maintains $156 price target.

Reiteration

Stephens & Co. Reiterates Overweight on Illumina, Maintains $156 Price Target

<a href="https://www.wsj.com/world/china/illumina-to-cut-100-million-in-costs-lowers-guidance-because-of-china-sales-ban-ff8b495a?mod=latest_headlines" title="https://www.wsj.com/world/china/illumina-to-cut-100-million-in-costs-lowers-guidance-because-of-china-sales-ban-ff8b495a?mod=latest_headlines">https://www.wsj.com/world/china/illumina-to-cut-100-million-in-costs-lowers-guidance-because-of-china-sales-ban-ff8b495a?mod=latest_headlines</a>

Global

'Illumina To Cut $100M In Costs, Lowers Guidance Because Of China Sales Ban; Beijing Banned Imports Of Illumina's Gene-Sequencing Machines In Response To U.S. Tariffs; Cuts 2025 Adjusted Earnings Guidance To $4.50 A Share' - WSJ

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class North America Index (formerly part of the Dow Jones Sustainability Indices), and recognized for the fourth year in a row as a Sustainability Yearbook Member. Illumina, which scored in the top 15% of the Best-in-Class World Index, also ranked as the highest-scoring US company in the&nbsp;Life Sciences Tools &amp; Services Sector.
The Dow Jones Best-in-Class Indices are&nbsp;based on the S&amp;P Global Corporate Sustainability Assessment annual evaluation of companies' sustainability practices. The Best-in-Class Indices represent the top 10% of each industry in the World Index and the top 20% for the North America Index.

Illumina Named To Dow Jones Best-In-Class World And North America Indices For Sixth Year

11 analysts have expressed a variety of opinions on Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $143.91, a high estimate of $247.00, and a low estimate of $90.00. This current average has decreased by 10.97% from the previous average price target of $161.64. 
<img src="https://www.benzinga.com/files/images/story/2025/1741179712_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Illumina's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$136.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$247.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$135.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Illumina. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Illumina's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Illumina's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Discovering Illumina: A Closer Look</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>Financial Insights: Illumina</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Illumina's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -1.6% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Illumina's net margin excels beyond industry benchmarks, reaching 16.94%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Illumina's ROE excels beyond industry benchmarks, reaching 8.31%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Illumina's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.04% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Illumina's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.1.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Illumina: Insights From 11 Analyst Reviews

Baird analyst Catherine Ramsey maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Neutral and lowers the price target from $127 to $90.

Baird Maintains Neutral on Illumina, Lowers Price Target to $90

Earnings

Press Releases

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2024

Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference

Illumina unveils first-of-its-kind spatial transcriptomics technology

Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions

Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology

Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year

Illumina addresses recent developments in China

Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery

Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

AKYA

CMBM

CSCO

DOMO

FTSW

ICLR

PRAH

QTRX

SFSF

YDLE

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Illumina

Noticias

Últimas noticias sobre Illumina (NASDAQ:ILMN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL